Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 203-808-3 | CAS number: 110-85-0
Sensitisation data (human)
Administrative data
- Endpoint:
- sensitisation data (humans)
- Type of information:
- experimental study
- Adequacy of study:
- supporting study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Review by authorities (EU RAR, 2005)
Data source
Reference
- Reference Type:
- publication
- Title:
- European Union Risk Assessment report - Piperazine
- Author:
- EU RAR
- Year:
- 2 005
- Bibliographic source:
- Institute for Health and Consumer Protection, European Chemicals Bureau, Existing Substances
Materials and methods
- Type of sensitisation studied:
- skin
- Study type:
- case report
Test guideline
- Qualifier:
- no guideline followed
- Principles of method if other than guideline:
- Case studies of patients with allergic dermatitis
- GLP compliance:
- not specified
Test material
- Reference substance name:
- Piperazine
- EC Number:
- 203-808-3
- EC Name:
- Piperazine
- Cas Number:
- 110-85-0
- Molecular formula:
- C4H10N2
- IUPAC Name:
- piperazine
Constituent 1
Method
- Type of population:
- other: Both general public after medical treatment and occupational exposure.
- Ethical approval:
- not applicable
- Subjects:
- Patients treated with piperazine containing antihelmintics, and people with occupational dermal exposure to piperazine
Results and discussion
- Results of examinations:
- Several cases of allergic dermatitis after contact with, or treatment with piperazine containing substances have been reported.
Applicant's summary and conclusion
- Conclusions:
- Piperazine is a dermal sensitiser in humans.
- Executive summary:
In the EU Risk Assessment Report for piperazine several case reports of allergic dermatitis havee been documented. The reports concern patients treated with piperazine, or workers exposed to piperazine. It can be concluded that piperazine is a dermal sensitiser in humans.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
